QRFPR and prostate carcinoma: QRFPR, also named GPR103, activates glutamine RF−amide peptide (QRFP), is over-expressed in human prostate cancer, and stimulates the neuroendocrine differentiation and the migration of androgen-independent prostate cancer cells (31, 32).